Page 27 - Intersurgical Product Catalogue UK Edition15A
P. 27

Breathing Filters, HMEs and HMEFs • Breathing Filters
Use of Breathing Filters
Breathing  lters provide an effective barrier that prevent cross contamination between patients, respiratory breathing systems, equipment and the clinical environment. Their use is widely recognised as bene cial and is recommended by a number of Anaesthetic Associations1.
The threat to patients
Patients who require an arti cial airway have their natural physiological protection bypassed. This will increase the
risk of cross contamination between patients and healthcare equipment. The cross contamination of patients via an anaesthetic system has been reported, and documented areas of concern regarding infection includes Hepatitis C, Mycobacterium tuberculosis, blood in sputum and the SARS virus.
Critically ill patients are commonly at risk of infection and particularly from Ventilator Associated Pneumonia (V.A.P.). This nosocomial infection increases morbity and potential mortality as well as the cost of treating the patient. The strategic use of an ef cient breathing  lter will provide an effective barrier between patients, breathing systems and ventilatory equipment.
Proven ef ciency
Essential requirements
The Intersurgical range of breathing  lters offers a choice of electrostatic and pleated mechanical  lters with a range of patient connections, providing a choice of products to meet various clinical situations.
• Independently validated Filtration Ef ciency2
• Proven  ltration against Mycobacterium tuberculosis • and Hepatitis C
• Proven ef ciency not affected by anaesthetic agent • Safe inert material
Option of patient connections – conveniently packed
• and ready for use
• Lightweight – reducing patient trauma
• Low compressible volume – reducing rebreathing of CO2 • Low resistance to  ow – over 24 hours
• Safe, secure ISO connectors
Compliance to all relevant international standards
Filtration ef ciency
Filtration performance is determined by independent microbiological testing against clinically relevant bacterial and viral challenges. The level of breakthrough of the challenge determines the ef ciency. This ef ciency is reported as a percentage based upon this break-through.
The Intersurgical range of breathing  lters has been designed for
the protection of the patient, breathing system and equipment.
They have been independently tested and proven to be highly
ef cient in preventing the passage of bacteria and viruses.
Clinically relevant testing is carried out on all products using
Bacillus subtilis (1.0μm x 0.7μm) and Ø174 bacteriophage,
additional testing includes Mycobacterium tuberculosis (0.3μm
x 1.0μm), Hepatitis C (0.03μm) and MS-2 coliphage (0.02μm). 100,000 These tests provide you with clinically relevant information
99% 99.9% 99.99% 99.999%
Number of organisms challenging the  lter
to allow evidence-based decisions to be made on the most appropriate product to meet your clinical requirements.
Potential infectious viruses [Particle sizes μ microns] Coliphage T1 [0.017μ]
MS-2 coliphage [0.02μ] Hepatitis C [0.03μ] Adenovirus [0.07μ]
Potential infectious bacteria [Particle sizes μ microns] Mycobacterium tuberculosis
[0.3μ x 1.0μ smallest size] Serratia marcescens [0.45μ]
Pseudomonas aeruginosa [0.5μ] Brevundimonas diminuta [0.3μ]
1. Association of Anaesthetists of Great Britain and Ireland 1996. Danish Society of Anaesthetists 1998. French Society of Anaesthetists 1998.
2. All  lters are independently validated for  ltration ef ciency at the Health Protection Agency, Porton Down, Salisbury, Wiltshire, U.K and Nelson Laboratories Inc, USA. All quoted performance  gures are mean values.
Contact us 0118 9656 300 • •
Number of organisms passing through the  lter
HIV [0.11μ]
Cytomegalovirus (CMV) [0.1μ] Orthomyxovirus [0.1μ]
Staphylococcus aureus [1.0μ]
Bacillus subtilis [1.0μ x 0.7μ]
Ef ciency of the  lter

   25   26   27   28   29